At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 28 enrolled
Drug / intervention
HP802-247biological
Likely dose
HP802-247 260 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study Investigating the Survival of HP802-247 Allogeneic Cells in Excisional Acute Cutaneous Wounds
In Brief
A Phase 1 clinical trial evaluating HP802-247 for Normal Female Volunteers. Completed, enrolled 28 participants across 1 site.
Detailed Summary
The goal for this study is to examine the persistence of growth arrested,allogeneic,male-donor keratinocytes and fibroblasts when applied as product HP802-247 to the surface of acute excisional wounds in health female volunteers, as measured using Y-STR for detection of Y-chromosome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNormal Female Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartSep 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedAug 30, 2010
Enrollment StartSep 1, 2010
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.8 years ago
Interventions
HP802-247biological
One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.